Disclosed are compositions, in particular, organoid compositions, derived from more than one donor cell. Further disclosed are methods of making compositions, for example, organoid compositions, that comprise a differentiated cell population derived from more than one donor cell. Donor cells may include, for example, a precursor cell such as an embryonic stem cell or other precursor cell. The disclosed methods use synchronization conditions to produce a synchronized pooled-precursor cell population, which may then be differentiated into an organoid composition. Methods of using the compositions are also disclosed.

The present invention provides a nerve cell device in which early observation of nerve activity (spikes, bursts, and the like) is made possible and the measured electric strength is increased by cultivating neurons upon a cell scaffold. By using this nerve cell device, imaging of intracellular signaling is also possible.

A method and a device allow measurement of the pH value of a solution. The method includes illuminating a solution containing a pH indicator and a pH changer with light emitted from a light emitting element, receiving light transmitted through the solution with a light receiving element, measuring absorbance with monochromatic light selectively from the received transmitted light, and calculating a pH value corresponding to the measured absorbance based on a predefined absorbance table. The device includes an illuminator that illuminates a solution containing a pH indicator and a pH changer with light emitted from a light emitting element, a light receiver that receives light transmitted through the solution, a measurer that measures absorbance with light with a wavelength of monochromatic light selectively from the received transmitted light, and a calculator that calculates a pH value corresponding to the absorbance measured by the measurer based on a predefined absorbance table.

A developmental toxicity screening assay using spatially organized cardiac organoids with contracting cardiomyocytes in the center surrounded by stromal cells distributed along the pattern perimeter engineered from human induced pluripotent stem cells (hiPSCs). Cardiac organoids generated from 600 μm-diameter circles were used as a developmental toxicity screening assay for the quantification of the embryotoxic potential of nine pharmaceutical compounds. The cardiac organoids were demonstrated as having a potential use as an in vitro platform for studying organoid structure-function relationships, developmental processes, and drug-induced cardiac developmental toxicity.

The present disclosure, in some aspects, is directed to methods for screening and identifying compounds that modulate one or more characteristics associated with a condensate comprising a RBM20 polypeptide and/or the RBM20 polypeptide. In other aspects, the disclosure is directed to systems and composition components thereof, such as cellular models useful for the methods described herein.

Disclosed are methods for making a vascularized hollow organ derived from human intestinal organoid (HIOs). The HIOs may be obtained from human embryonic stem cells (ESC's) and/or induced pluripotent stem cells (iPSCs), such that the HIO forms mature intestinal tissue. Also disclosed are methods for making a human intestinal tissue containing a functional enteric nervous system (ENS).

An object of the present invention is to provide a novel method which enables convenient preparation of cells exhibiting functions close to that of intestinal epithelial cells of living bodies, and use of the method. The differentiation of induced pluripotent stem cells into intestinal epithelial cells is induced by step of differentiating induced pluripotent stem cells into endoderm-like cells; step of differentiating the endoderm-like cells obtained in step into intestinal stem cell-like cells; and step of differentiating the intestinal stem cell-like cells obtained in step into intestinal epithelial cell-like cells, wherein step includes culture in the presence of a MEK1 inhibitor, a DNA methyltransferase inhibitor, a TGF-β receptor inhibitor, and EGF and under the condition that cAMP is supplied to the cells.

The present invention provides a method of measuring the quality of therapeutic cells through real-time glutathione monitoring.

The present disclosure provides cell-based compositions for treating diabetes, methods for identifying cells that preferentially differentiate into endoderm cells, and methods for preparing insulin-producing pancreatic cells, as well as related methods of use for treating diseases related to insulin deficiency.

The present disclosure provides cell-based compositions for treating diabetes, methods for identifying cells that preferentially differentiate into endoderm cells, and methods for preparing insulin-producing pancreatic cells, as well as related methods of use for treating diseases related to insulin deficiency.